Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

MLA

Alberto Ocaña, et al. “Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.” Frontiers in Oncology, vol. 11, Feb. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2021.827625.

APA

Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, Antonio Antón, Mauro Mansutti, Joan Albanell, María Teresa Martínez, Ainhara Lahuerta, Giancarlo Bisagni, Begoña Bermejo, Vladimir Semiglazov, Marc Thill, Arlene Chan, Serafin Morales, Jesús Herranz, Ignacio Tusquets, Massimo Chiesa, Rosalía Caballero, Pinuccia Valagussa, … Luca Gianni. (2022). Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.827625

Chicago

Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, Antonio Antón, Mauro Mansutti, Joan Albanell, María Teresa Martínez, et al. 2022. “Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.” Frontiers in Oncology 11 (February). doi:10.3389/fonc.2021.827625.